Literature DB >> 17353209

Level of renal function and serum erythropoietin levels independently predict anaemia post-renal transplantation.

Kim T Sinnamon1, Aisling E Courtney, A Peter Maxwell, Peter T McNamee, Geraldine Savage, Damian G Fogarty.   

Abstract

BACKGROUND: Post-renal transplant anaemia is a potentially reversible cardiovascular risk factor. Graft function, immunosuppressive agents and inhibition of the renin-angiotensin system have been implicated in its aetiology. The evaluation of erythropoietin (EPO) levels may contribute to understanding the relative contributions of these factors.
METHODS: Two-hundred and seven renal transplant recipients attending the Belfast City Hospital were studied. Clinical and laboratory data were extracted from the medical records and laboratory systems.
RESULTS: Of the 207 patients (126 male), 47 (22.7%) were found to be anaemic (males, haemoglobin (Hb)<12 g/dl, females Hb<11 g/dl). The anaemic group had a significantly higher mean serum creatinine level (162.8 micromol/l vs 131.0 micromol/l, P<0.001) and lower mean estimated glomerular filtration rate (eGFR) (41.5 ml/min vs 54.9 ml/min, P<0.001) than the non-anaemic group. Individual immunosuppressive regimens were comparable between those with and those without anaemia. Angiotensin converting enzyme inhibitor (ACE-I) or angiotensin receptor blocker (ARB) administration was not more prevalent in those with anaemia compared with those without (36.2 vs 38.8%, P=0.88). There was a significant inverse correlation between Hb levels and serum EPO levels (R=-0.29, P<0.001), but not between EPO levels and eGFR (R=0.02, P=0.74). Higher EPO levels were predictive of anaemia, independent of eGFR in multivariate analysis.
CONCLUSION: Anaemia is common in post-renal transplant patients. The levels of renal function and serum EPO and not immunosuppressive regimens or ACE-I/ARB use, are strong and independent predictors of anaemia.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17353209     DOI: 10.1093/ndt/gfm100

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  6 in total

Review 1.  Pottransplantation anemia: management and rationale.

Authors:  Wolfgang C Winkelmayer; Anil Chandraker
Journal:  Clin J Am Soc Nephrol       Date:  2008-03       Impact factor: 8.237

2.  Safety and efficacy of administering the maximal dose of candesartan in renal transplant recipients.

Authors:  Masayoshi Okumi; Noritaka Kawada; Naotsugu Ichimaru; Harumi Kitamura; Toyofumi Abe; Ryoichi Imamura; Yasuyuki Kojima; Yukito Kokado; Yoshitaka Isaka; Hiromi Rakugi; Norio Nonomura; Toshiki Moriyama; Shiro Takahara
Journal:  Clin Exp Nephrol       Date:  2011-08-05       Impact factor: 2.801

3.  Serum erythropoietin level and mortality in kidney transplant recipients.

Authors:  Miklos Z Molnar; Adam G Tabak; Ahsan Alam; Maria E Czira; Anna Rudas; Akos Ujszaszi; Gabriella Beko; Marta Novak; Kamyar Kalantar-Zadeh; Csaba P Kovesdy; Istvan Mucsi
Journal:  Clin J Am Soc Nephrol       Date:  2011-10-06       Impact factor: 8.237

4.  Anemia and low-grade inflammation in pediatric kidney transplant recipients.

Authors:  Jenni Miettinen; Juuso Tainio; Timo Jahnukainen; Mikko Pakarinen; Jouni Lauronen; Hannu Jalanko
Journal:  Pediatr Nephrol       Date:  2016-08-30       Impact factor: 3.714

5.  Negative effects of anemia on quality of life and its improvement by complete correction of anemia by administration of recombinant human erythropoietin in posttransplant patients.

Authors:  Noritaka Kawada; Toshiki Moriyama; Naotsugu Ichimaru; Ryoichi Imamura; Isao Matsui; Yoshitsugu Takabatake; Yasuyuki Nagasawa; Yoshitaka Isaka; Yasuyuki Kojima; Yukito Kokado; Hiromi Rakugi; Enyu Imai; Shiro Takahara
Journal:  Clin Exp Nephrol       Date:  2009-04-08       Impact factor: 2.801

6.  Risk factors of post renal transplant anaemia among Sudanese patients, a study in three renal transplant centres.

Authors:  Amin S I Banaga; Mohamed E A Yousif; Khalifa Elmusharaf
Journal:  BMC Nephrol       Date:  2011-08-09       Impact factor: 2.388

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.